Imatinib is a small molecule commercialized by Aerovate Therapeutics, with a leading Phase III program in Pulmonary Arterial Hypertension. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Imatinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Imatinib is expected to reach an annual total of $405 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Imatinib (AV-101) is under development for the treatment of pulmonary arterial hypertension (PAH). It is administered through the inhalational route as dry aerosol powder formulation. It acts by targeting Bcr-Abl tyrosine kinase, platelet derived growth factor receptor and mast/stem cell growth factor receptor kit.
Aerovate Therapeutics Overview
Aerovate Therapeutics is a biopharmaceutical company that focuses on developing treatments for rare cardiopulmonary diseases. It is headquartered in Boston, Massachusetts, the US.
The operating loss of the company was US$23 million in FY2021, compared to an operating loss of US$8.9 million in FY2020. The net loss of the company was US$23 million in FY2021, compared to a net loss of US$9.6 million in FY2020.
For a complete picture of Imatinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.